Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Moderna, Inc. reported its financial and operational results for the first quarter of 2026, reflecting a mixed performance with notable developments in both commercial execution and pipeline advancement.</li><li>The company achieved total revenues of $400 million in the quarter, significantly higher year-over-year by $300 million, primarily boosted by international sales attributable to long-term strategic partnerships, notably with the United Kingdom government.</li><li>This international market represented approximately 80% of revenue.</li></ul>

Moderna, Inc. reported its financial and operational results for the first quarter of 2026, reflecting a mixed performance with notable developments in both commercial execution and pipeline advancement.The company achieved total revenues of $400 million in the quarter, significantly higher year-over-year by $300 million, primarily boosted by international sales attributable to long-term strategic partnerships, notably with the United Kingdom government.This international market represented approximately 80% of revenue.

Can Moderna Sustain Up To 10% Growth As Vaccine Demand Shifts?

<ul><li>Moderna briefly returned to Wall Street’s outbreak-trade spotlight after a small hantavirus cluster linked to a cruise ship triggered a sudden stock spike.</li><li>The reaction was dramatic because the actual public-health risk appeared limited, with WHO officials assessing the broader threat as low and analysts warning that hantavirus is unlikely to become a meaningful revenue opportunity for the company.</li><li>Yet the market response showed how deeply COVID-era memories still shape investor behavior.</li></ul>

Moderna briefly returned to Wall Street’s outbreak-trade spotlight after a small hantavirus cluster linked to a cruise ship triggered a sudden stock spike.The reaction was dramatic because the actual public-health risk appeared limited, with WHO officials assessing the broader threat as low and analysts warning that hantavirus is unlikely to become a meaningful revenue opportunity for the company.Yet the market response showed how deeply COVID-era memories still shape investor behavior.

Moderna Stock Suddenly Surged After A Hantavirus Cruise Ship Scare—Here’s Why!

<ul><li>Moderna, Inc. reported its financial results for the fourth quarter and full year 2025, highlighting both progress and challenges.</li><li>The company generated $1.9 billion in revenue, predominantly from sales of its COVID vaccines, Spikevax and mNEXSPIKE.</li><li>This marked a significant decrease from prior years, reflecting a broader trend of declining COVID vaccine demand.</li></ul>

Moderna, Inc. reported its financial results for the fourth quarter and full year 2025, highlighting both progress and challenges.The company generated $1.9 billion in revenue, predominantly from sales of its COVID vaccines, Spikevax and mNEXSPIKE.This marked a significant decrease from prior years, reflecting a broader trend of declining COVID vaccine demand.

Moderna’s Oncology Bets Are Entering a Crucial Phase—Do the Upcoming Readouts Change the Long-Term Story?

<ul><li>Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline.</li><li>The agency issued a refusal-to-file letter, citing the absence of an “adequate and well-controlled” trial.</li><li>The market read it as a product setback.</li></ul>

Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline.The agency issued a refusal-to-file letter, citing the absence of an “adequate and well-controlled” trial.The market read it as a product setback.

Moderna’s Filing Was Rejected — But The REAL Story Is FDA Dynamics!

<ul><li>Moderna surprised investors with a better-than-expected 2025 revenue pre-announcement of approximately $1.9 billion, above the midpoint of its previous guidance.</li><li>However, the stock fell 3.5% following the update, as Wall Street remained unconvinced that cost cuts—despite reducing 2025 operating expenses to an estimated $4.9 billion—are enough to meet the company’s target of reaching cash flow breakeven by 2028.</li><li>While Moderna maintained its outlook for up to 10% revenue growth in 2026, analysts such as those at Jefferies are modeling breakeven timelines in 2029 or 2030 instead, citing persistent cash burn and uncertainty around vaccine demand post-COVID.</li></ul>

Moderna surprised investors with a better-than-expected 2025 revenue pre-announcement of approximately $1.9 billion, above the midpoint of its previous guidance.However, the stock fell 3.5% following the update, as Wall Street remained unconvinced that cost cuts—despite reducing 2025 operating expenses to an estimated $4.9 billion—are enough to meet the company’s target of reaching cash flow breakeven by 2028.While Moderna maintained its outlook for up to 10% revenue growth in 2026, analysts such as those at Jefferies are modeling breakeven timelines in 2029 or 2030 instead, citing persistent cash burn and uncertainty around vaccine demand post-COVID.

Moderna Stock Falls Despite Revenue Beat: Here’s Why Investors Remain Cautious!

United States

Moderna, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Moderna (MRNA US)

Can Moderna Sustain Up To 10% Growth As Vaccine Demand Shifts?

Moderna, Inc. reported its financial and operational results for the first quarter of 2026, reflecting a mixed performance with notable...

Baptista Research

Moderna Stock Suddenly Surged After A Hantavirus Cruise Ship Scare—Here’s Why!

Moderna briefly returned to Wall Street’s outbreak-trade spotlight after a small hantavirus cluster linked to a cruise ship triggered a sudden...

Baptista Research

Moderna’s Oncology Bets Are Entering a Crucial Phase—Do the Upcoming Readouts Change the Long-Term Story?

Moderna, Inc. reported its financial results for the fourth quarter and full year 2025, highlighting both progress and challenges. The company...

Baptista Research

Moderna’s Filing Was Rejected — But The REAL Story Is FDA Dynamics!

Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued a...

Baptista Research

Moderna Stock Falls Despite Revenue Beat: Here’s Why Investors Remain Cautious!

Moderna surprised investors with a better-than-expected 2025 revenue pre-announcement of approximately $1.9 billion, above the midpoint of its...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)